Molecular Features of Gastroenteropancreatic Neuroendocrine Carcinoma: A Comparative Analysis with Lung Neuroendocrine Carcinoma and Digestive Adenocarcinomas

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2024 Mar 8

PMID 38455367

Authors

Jianwei Zhang

Hanxiao Chen

Junli Zhang

Sha Wang

Yanfang Guan

WenGuang Gu

Jie Li

Xiaotian Zhang

Jian Li

Xicheng Wang

Zhihao Lu

Jun Zhou

Zhi Peng

Yu Sun

Yang Shao

Lin Shen

Minglei Zhuo

Ming Lu

Affiliations

Soon will be listed here.

Abstract

Objective: There is an ongoing debate about whether the management of gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) should follow the guidelines of small-cell lung cancer (SCLC). We aim to identify the genetic differences of GEPNEC and its counterpart.

Methods: We recruited GEPNEC patients as the main cohort, with lung NEC and digestive adenocarcinomas as comparative cohorts. All patients undergone next-generation sequencing (NGS). Different gene alterations were compared and analyzed between GEPNEC and lung NEC (LNEC), GEPNEC and adenocarcinoma to yield the remarkable genes.

Results: We recruited 257 patients, including 99 GEPNEC, 57 LNEC, and 101 digestive adenocarcinomas. Among the mutations, , , , , and were found to have different gene alterations between GEPNEC and LNEC samples. Specific genes for each site were revealed: gastric NEC ( amplification), colorectal NEC ( mutation), and bile tract NEC ( mutation). The gene disparities between small-cell NEC (SCNEC) and large-cell NEC (LCNEC) were and . Digestive adenocarcinoma was also compared with GEPNEC and suggested , , and as significant genes. The / mutation pattern was associated with first-line effectiveness. Putative targetable genes and biomarkers in GEPNEC were identified in 22.2% of the patients, and they had longer progression-free survival (PFS) upon targetable treatment [12.5 months 3.0 months, HR=0.40 (0.21-0.75), P=0.006].

Conclusions: This work demonstrated striking gene distinctions in GEPNEC compared with LNEC and adenocarcinoma and their clinical utility.

Citing Articles

Development and validation of a nomogram to predict overall survival of gastroenteropancreatic neuroendocrine carcinoma: a SEER database analysis.

Chen Q, Guo Y, Wang Z, Chen X, Tian C, Zheng J Transl Cancer Res. 2024; 13(9):4678-4693.

PMID: 39430841 PMC: 11483443. DOI: 10.21037/tcr-23-2215.

References

. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017; 7(8):818-831. PMC: 5611790. DOI: 10.1158/2159-8290.CD-17-0151. View

Burkart J, Owen D, Shah M, Abdel-Misih S, Roychowdhury S, Wesolowski R . Targeting Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. J Natl Compr Canc Netw. 2018; 16(9):1035-1040. DOI: 10.6004/jnccn.2018.7043. View

Ohmoto A, Sato Y, Asaka R, Fukuda N, Wang X, Urasaki T . Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma. Mod Pathol. 2021; 34(11):1979-1989. PMC: 8514330. DOI: 10.1038/s41379-021-00869-9. View

Koh J, Nam S, Kwak Y, Kim G, Kim K, Lee B . Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas. J Pathol. 2020; 253(1):94-105. DOI: 10.1002/path.5556. View

Takizawa N, Ohishi Y, Hirahashi M, Takahashi S, Nakamura K, Tanaka M . Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor. Hum Pathol. 2015; 46(12):1890-900. DOI: 10.1016/j.humpath.2015.08.006. View

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

Makuuchi R, Terashima M, Kusuhara M, Nakajima T, Serizawa M, Hatakeyama K . Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach. Biomed Res. 2017; 38(1):19-27. DOI: 10.2220/biomedres.38.19. View

Kimura T, Miyamoto H, Fukuya A, Kitamura S, Okamoto K, Kimura M . Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma. Clin J Gastroenterol. 2016; 9(4):261-5. DOI: 10.1007/s12328-016-0655-6. View

10.

Elvebakken H, Hjortland G, Garresori H, Andresen P, Janssen E, Vintermyr O . Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms. J Neuroendocrinol. 2023; 35(4):e13256. DOI: 10.1111/jne.13256. View

11.

Furlan D, Sahnane N, Mazzoni M, Pastorino R, Carnevali I, Stefanoli M . Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum. Virchows Arch. 2012; 462(1):47-56. DOI: 10.1007/s00428-012-1348-2. View

12.

Brennan S, Gregory D, Stillie A, Herschtal A, Manus M, Ball D . Should extrapulmonary small cell cancer be managed like small cell lung cancer?. Cancer. 2010; 116(4):888-95. DOI: 10.1002/cncr.24858. View

13.

Olevian D, Nikiforova M, Chiosea S, Sun W, Bahary N, Kuan S . Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. Hum Pathol. 2016; 49:124-34. DOI: 10.1016/j.humpath.2015.11.004. View

14.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

15.

Xing J, Ying H, Li J, Gao Y, Sun Z, Li J . Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System. Front Oncol. 2020; 10:132. PMC: 7059119. DOI: 10.3389/fonc.2020.00132. View

16.

Girardi D, Silva A, Rego J, Coudry R, Riechelmann R . Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev. 2017; 56:28-35. DOI: 10.1016/j.ctrv.2017.04.002. View

17.

Jesinghaus M, Konukiewitz B, Keller G, Kloor M, Steiger K, Reiche M . Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Mod Pathol. 2017; 30(4):610-619. DOI: 10.1038/modpathol.2016.220. View

18.

Karkouche R, Bachet J, Sandrini J, Mitry E, Penna C, Cote J . Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol. 2012; 24(12):1430-7. DOI: 10.1097/MEG.0b013e3283583c87. View

19.

Lu M, Zhang P, Zhang Y, Li Z, Gong J, Li J . Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clin Cancer Res. 2020; 26(10):2337-2345. DOI: 10.1158/1078-0432.CCR-19-4000. View

20.

Mosele F, Remon J, Mateo J, Westphalen C, Barlesi F, Lolkema M . Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020; 31(11):1491-1505. DOI: 10.1016/j.annonc.2020.07.014. View